¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Antibody Directed Enzyme Prodrug Therapy"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • antibody excess zone
    Ç×ü°úÀ×±¸¿ª
  • antibody half-life
    Ç×ü¹Ý°¨±â
  • antibody identification test
    Ç×üȮÀΰ˻ç
  • antibody removal
    Ç×üÁ¦°Å
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • antibody synthesis
    Ç×üÇÕ¼º
  • antibody valence
    Ç×ü°áÇÕ°¡
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-mediated hypersensitivity
    Ç×ü¸Å°³°ú¹Î¼º
  • antibody-mediated immunity
    Ç×ü¸Å°³¸é¿ª
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • anticardiolipin antibody
    Ç×Ä«µð¿À¸®ÇÉÇ×ü
  • anti-double stranded deoxyribonucleic acid antibody
    Ç×ÀÌÁß°¡´ÚDNAÇ×ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • reality therapy
    Çö½Ç¿ä¹ý
  • replacement therapy
    º¸»ó¿ä¹ý
  • self-control therapy
    ÀÚ±âÁ¶Àý¿ä¹ý
  • spiritual therapy
    ¿µÀû¿ä¹ý
  • supportive therapy
    ÁöÁö¿ä¹ý
  • symptomatic therapy
    ´ëÁõ¿ä¹ý
  • systemic therapy
    Àü½Å¿ä¹ý
  • therapy
    ¿ä¹ý
  • thrombolytic therapy
    Ç÷Àü¿ëÇØ¿ä¹ý
  • topical therapy
    ±¹¼Ò¿ä¹ý
  • ultrasonic therapy
    (¢¡ultrasound therapy) ÃÊÀ½ÆÄ¿ä¹ý
  • ultrasound therapy
    ÃÊÀ½ÆÄ¿ä¹ý
  • vaccine therapy
    ¹é½Å¿ä¹ý
  • will therapy
    ÀÇÁö¿ä¹ý
  • work therapy
    ÀÛ¾÷¿ä¹ý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • anti-sm antibody
    Ç×Sm Ç×ü(ù÷¡­ù÷ô÷)
  • antibody
    Ç×ü(ù÷ô÷)
  • antibody
    Ç×ü(ù÷ô÷)
  • antibody
    Ç×ü
  • antibody absorption
    Ç×üÈíÂø
  • antibody absorption test
    Ç×üÈí¼ö½ÃÇè(ù÷ô÷ýåâ¥ãËúÐ).
  • antibody binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody combining site
    Ç×ü°áÇÕºÎ(ù÷ô÷Ì¿ùêÝ»).
  • antibody deficiency syndrome
    Ç×ü°áÇÌÁõÈıº(ù÷ô÷ÌÀù¹ñøý¦ÏØ).
  • antibody dependent cell mediated cytotoxicity
    Ç×üÀÇÁ¸ ¼¼Æ÷¸Å°³ ¼¼Æ÷µ¶¼º.
  • antibody detection
    Ç×ü°ËÃâ
  • antibody diversity
    Ç×ü´Ù¾ç¼º.
  • antibody excess
    Ç×ü°úÀ×(ù÷ô÷Φí¥).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • activity therapy
    Ȱµ¿¿ä¹ý(¡­èþÛö).
  • acupuncture therapy
    ħ¼ú¿ä¹ý.
  • adaptive radiation therapy
    ÀûÀÀ¹æ»ç¼±Ä¡, ¼øÀÀ¹æ»ç¼±Ä¡·á
  • adjuvant therapy
    º¸Á¶¿ä¹ý, º¸Á¶Ä¡·á
  • adjuvant therapy
    º¸Á¶¿ä¹ý.
  • androgen therapy
    ³²¼ºÈ£¸£¸ó ¿ä¹ý
  • antiandrogenic therapy
    Ç׳²¼ºÈ£¸£¸ó¿ä¹ý.
  • anticoagulant therapy
    Ç×ÀÀ°í¿ä¹ý.
  • antiestrogen therapy, for sexual dysfunction
    Ç׿¡½ºÆ®·Î°Õ ¿ä¹ý(¼º±â´ÉÀå¾ÖÀÇ)
  • antifungal therapy
    Ç×°õÆÎÀÌÄ¡·á
  • antimicrobial therapy
    Ç×±Õ¿ä¹ý(ù÷жèþÛö).
  • art therapy
    ¿¹¼ú¿ä¹ý
  • bacterial interference therapy
    ¼¼±Õ°£¼·Ä¡·á
  • behavior therapy
    Çൿ(ÇàÅÂ)Ä¡·á
  • behavioral - cognitive therapy
    Çൿ(ÇàÅÂ)ÀÎÁöÀû Ä¡·á
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • enzyme complex
    È¿¼Òº¹ÇÕü (ý£áÈÜÜùêô÷)
  • enzyme concentration
    È¿¼Ò³óµµ (ý£áÈÒØÓø)
  • enzyme conservation equation
    È¿¼Òº¸Á¸ ¹æÁ¤½Ä (ý£áÈÜÁðíÛ°ïïãÒ)
  • enzyme electrode
    È¿¼ÒÀü±Ø(ý£áÈï³Ð¿)
  • enzyme engineering
    È¿¼Ò°øÇÐ(ý£áÈÍïùÊ)
  • enzyme fractionation
    È¿¼ÒºÐȹ¹ý(ý£áÈÝÂüñÛö)
  • enzyme graph
    È¿¼Òµµ(ý£áÈÓñ)
  • enzyme immunoassay
    È¿¼Ò ¸é¿ª(ý£áÈØóæ¹)¾Æ½êÀÌ
  • enzyme induction
    È¿¼ÒÀ¯µµ(ý£áÈë¯Óô)
  • enzyme-inhibitor complex
    È¿¼Ò-ÀúÇØÁ¦ º¹ÇÕü (ý£áÈîÁúªð¥ÜÜùêô÷)
  • enzyme interconversion
    È¿¼Ò »óÈ£Àüȯ (ý£áÈßÓû»ï®üµ)
  • enzyme intermediates
    È¿¼Ò Áß°£Ã¼(ý£áÈñéÊàô÷)
  • enzyme kinetics
    È¿¼Ò¿ªµ¿ÇÐ(ý£áÈæ³ÔÑùÊ)
  • enzyme labeling
    È¿¼ÒÇ¥Áö(ý£áÈøöò½)
  • enzyme-linked immunosorbent assay
    È¿¼Ò¿¬°ü ¸é¿ªÈíÂø (ý£áÈ֤μØóæ¹ýåó·) ¾Æ½êÀÌ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
AAAE amino acid activating enzyme
ACE acetonitrile; acetylcholine esterase; acute cerebral encephalopathy; acute coronary event; adrenocor...
ACEDS angiotensin-converting enzyme dysfunction syndrome
ACEI angiotensin-converting enzyme inhibitor
AICE angiotensin I converting enzyme
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
ITU Intensive Therapy Unit
IIT Intensive insulin therapy
IORT Intra Operative Radiation Therapy
JCRT Joint Center for Radiation Therapy
LITT Laser-induced interstitial thermo-therapy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • electrical stimulation therapy
    Àü±â ÀÚ±Ø ¿ä¹ý
  • electroconvulsive therapy
    Àü±â °æ·Ã ¹æ¹ý, Àü±â °æ·Ã ¿ä¹ý, Àü±â °æ·Ã Ä¡·á
    1. Àü±â ¼ïÀÇ ¹æ¹ý¿¡ ÀÇÇØ¼­ °æ·ÃÀ» À¯¹ßÇÏ´Â Ä¡·á¹ý. 2. Àü·ù¸¦ ³ú¿¡ ÅëÇØ¼­ °æ·ÃÀ» À¯µµÇÏ´Â °Í. ÁÖ·Î Á¤µ¿ Àå¾ÖÀÇ Ä¡·á¿¡ »ç¿ëµÈ´Ù. Çö´ëÀÇ ½ÇÁö ÀÇ·á¿¡¼­´Â ±ÙÀ°ÀÌ¿ÏÁ¦ÀÇ Àû¿ë¿¡ ÀÇÇØ¼­ °æ·Ã Áõ»óÀ» ÃÖ¼ÒÇÑÀ¸·Î °æ°¨½ÃŲ´Ù.
  • electrogalvanic stimulation therapy
    °¥¹Ù´Ð Àü±â ÀÚ±Ø Ä¡·á
  • electron beam therapy
    ÀüÀÚ¼± Ä¡·á
  • endodontic therapy
    ±Ù°ü Ä¡·á
  • exercise therapy
    ¿îµ¿ Ä¡·á
  • extension therapy
    °ßÀÎ ¿ä¹ý
    Áö¼ÓÀûÀ¸·Î °ßÀηÂÀ» ÀÛ¿ë½ÃÄÑ ±ÙÀ°À» Ä¡·áÇÏ´Â ¹ý. ±ÙÀ°Àº Ÿ¹ÚÀ̳ª ¿Ü»ó ¶§ ÀåÃà ¹æÇâÀ¸·Î ´ÜÃàµÇ´Â ÀÏÀÌ ¸¹¾Æ¼­, ¿°ÁÂ, Á»ó, ±×¸®°í ¾î¶² Á¾·ùÀÇ °ñÀý¿¡¼­´Â ÀåÃà ¹æÇâÀ¸·Î Áö¼ÓÀûÀ¸·Î °ßÀÎÇÒ Çʿ䰡 ÀÖ´Ù. °£´ÜÇÑ °ßÀοä¹ýÀ¸·Î´Â ¹Ýâ°íÀÇ ÀÀ¿ëÀÌ ÀÖÀ¸¸ç, ±³Åë»ç°í ¶§ ¸¹ÀÌ ÀϾ´Â °æÃß ¿°Á¿¡´Â ¾Æ·¡ÅÎÀ» °íÁ¤½Ã۰í üÁßÀ» ÀÌ¿ëÇÏ´Â °ßÀαⰡ °í¾ÈµÇ¾î ÀÖ´Ù. ±× ¹Û¿¡ °­¼±À» Ȱ¿ëÇÏ¿© »À¿¡ Á÷Á¢ °ßÀηÂÀ» ¹ÌÄ¡´Â ¹æ¹ýµµ ÀÖ´Ù.
  • fluid therapy
    ¼ö¾× ¿ä¹ý
  • fluoride therapy
    ºÒ¼Ò Ä¡·á, ºÒ¼Ò óġ
  • heat and cold therapy
    ³Ã¿Â ¿ä¹ý
    Â÷°¡¿î ÆÐµå¿Í ¶ß°Å¿î ÆÐµå¸¦ ¹ø°¥¾Æ°¡¸ç º´¼Ò¿¡ ´ë°í Ç÷¾× ¼øÈ¯À» ÃËÁø½Ã۰í ÅëÁõÀ» ¿ÏÈ­½ÃŰ´Â ¹æ¹ý.
  • indirect pulp therapy
    °£Á¢ Ä¡¼ö Ä¡·á
  • infrared laser therapy
    Àû¿Ü¼± ·¹ÀÌÀú ¿ä¹ý
    µ¿ÀǾî=cold laser thera
  • initial therapy
    Ãʱâ Ä¡·á
  • insulin convulsive therapy combined
    Àν¶¸° °æ·Ã º´ÇÕ Ä¡·á, Àν¶¸° °æ·Ã º´ÇÕ ¿ä¹ý
  • irreversible occlusal therapy
    ºñ°¡¿ªÀûÀÎ ±³ÇÕ Ä¡·á, ºñ°¡¿ªÀû ±³ÇÕ Ä¡·á
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
antibody-coated bacteria test, urinary Fluorescent antibody technique for visualizing antibody-bacteria complexes in urine. The presence or absence of antibody-coated bacteria in urine correlates with localization of urinary tract infection in the kidney or bladder, respectively.
(12 Dec 1998)
antibody combining site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
antibody deficiency disease <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms.
See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency.
Synonym: antibody deficiency disease.
(05 Mar 2000)
antibody deficiency syndrome <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms.
See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency.
Synonym: antibody deficiency disease.
(05 Mar 2000)
antibody-dependent cell cytotoxicity The phenomenon of antibody-mediated target cell destruction by non-sensitised effector cells. The identity of the target cell varies, but it must possess surface IgG whose fc portion is intact. The effector cell is a "killer" cell possessing fc receptors. It may be a lymphocyte lacking conventional b- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.
(12 Dec 1998)
antibody-dependent enhancement Enhancement of viral infectivity caused by non-neutralizing antibodies. There are at least two mechanisms known to account for this: mediation by fc receptors (receptors, fc) or by complement receptors (receptors, complement). Either the virus is complexed with antiviral IgG and binds to fc receptors, or virus is coated with antiviral IgM and binds to complement receptors.
(12 Dec 1998)
antibody diversity The phenomenon of immense variability characteristic of antibodies, which enables the immune system to react specifically against the essentially unlimited kinds of antigens it encounters. Antibody diversity is accounted for by three main theories: 1) the germ line theory, which holds that each antibody-producing cell has genes coding for all possible antibody specificities, but expresses only the one stimulated by antigen; 2) the somatic mutation theory, which holds that antibody-producing cells contain only a few genes, which produce antibody diversity by mutation; and 3) the gene rearrangement theory, which holds that antibody diversity is generated by the rearrangement of variable region gene segments during the differentiation of the antibody-producing cells.
(12 Dec 1998)
antibody excess In a precipitation test, the presence of antibody in an amount greater than that required to combine with all of the antigen present.
(05 Mar 2000)
antibody-forming cell <immunology> B-cells (plasma cells) that are dedicated to producing secreted antibodies.
(09 Feb 1998)
antibody induced lysis <haematology> The term is imprecise and should not be used since there is confusion as to which mechanism is involved, i.e. Natural killing or complement lysis.
See: complement lysis, natural killer cells.
(09 Feb 1998)
antibody producing cell <immunology> A lymphocyte of the B series synthesising and releasing immunoglobulin. Equivalent to plasmacyte and plasma cell.
(18 Nov 1997)
antibody-producing cells Cells of the lymphoid series that can react with antigen to produce specific cell products called antibodies. Various cell subpopulations, often B-lymphocytes, can be defined, based on the different classes of immunoglobulins that they synthesise.
(12 Dec 1998)
antibody specificity The property of antibodies which enables them to react with some antigenic determinants and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
(12 Dec 1998)
antibody technology <molecular biology> Techniques for the synthesis of polyclonal and monoclonal antibodies for use in research, diagnostics and therapeutics.
(09 Feb 1998)
antigen-antibody complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble.
Immune complexes activate complement through the classical pathway.
See: glomerulonephritis, Arthus reaction, type III hypersensitivity.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á